Immuron Limited operates as a biopharmaceutical company. The Company focuses on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. Immuron's technology platform is developing and producing an orally stable therapeutic for various immune mediated and inflammatory disorders.

Immuron CEO presentation to Virtual Investor Summit

Results of Meeting

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Immuron Ltd (IMC AU)

Immuron CEO presentation to Virtual Investor Summit

Results of Meeting

2024 AGM Presentation

Change of Director's Interest Notice (DP RS)

Notification of cessation of securities - IMC

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)